Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-nmvwc Total loading time: 0 Render date: 2024-07-02T16:58:54.967Z Has data issue: false hasContentIssue false

13 - The Use of Antipsychotic Drugs in Bipolar II Disorder

from Section 1 - Domain Chapters

Published online by Cambridge University Press:  17 December 2018

By
Eduard Vieta
Edited by
Gordon Parker
Gordon Parker
Affiliation:
University of New South Wales, Sydney
Get access
Type
Chapter
Information
Bipolar II Disorder
Modelling, Measuring and Managing
 , pp. 143 - 150
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Altshuler, L. L., Post, R. M., Leverich, G. S. et al. (1995). Antidepressant-induced mania and cycle acceleration: a controversy revisited. American Journal of Psychiatry, 152, 1130–8.Google ScholarPubMed
Brugue, E. and Vieta, E. (2007). Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications. Progress in Neuropsychopharmacological and Biological Psychiatry, 31, 275–82.Google Scholar
Calabrese, J. R., Pikalov, A., Streicher, C., et al. (2017) Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. European Neuropsychopharmacology 27, 865–76.Google Scholar
Catalá-López, F., Gènova-Maleras, R., Vieta, E. et al. (2013) The increasing burden of mental and neurological disorders. European Neuropsychopharmacology, 23, 1337–9.Google Scholar
Colom, F., Vieta, E., Daban, C. et al. (2006). Clinical and therapeutic implications of predominant polarity in bipolar disorder. Journal of Affective Disorders 93, 13–17.Google Scholar
Cruz, N., Sanchez-Moreno, J., Torres, F. et al. (2010). Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. International Journal of Neuropsychopharmacology, 13, 5–14.Google Scholar
Cruz, N., Vieta, E., Comes, M. et al. (2008). EMBLEM Advisory Board. Rapid-cycling bipolar I disorder: course and treatment outcome of a large sample across Europe. Journal of Psychiatry Research, 42, 1068–75.Google Scholar
De Dios, C., Ezquiaga, E., García, A. et al. (2010). Time spent with symptoms in a cohort of bipolar disorder outpatients in Spain: a prospective, 18-month study. Journal of Affective Disorders, 125, 74–81.Google Scholar
Dunner, D. (1979). Rapid-cycling manic depressive illness. Psychiatric Clinics of North America, 2, 461–7.Google Scholar
Durgam, S., Earley, W., Lipschitz, A., et al. (2016) An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. American Journal of Psychiatry. 173, 271–81.CrossRefGoogle ScholarPubMed
El-Mallakh, R., Weisler, R. H., Townsend, M. et al. (2006). Bipolar II disorder: current and future treatment options. Annals of Clinical Psychiatry, 18, 259–66.Google Scholar
García-Amador, M., Pacchiarotti, I., Valenti, M. et al. (2006). Role of aripiprazole in treating mood disorders. Expert Review of Neurotherapeutics, 6, 1777–83.Google Scholar
Garriga, M., Solé, E., González-Pinto, A., et al. (2017). Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: results from a pilot, randomized controlled trial. European Neuropsychopharmacology 27, 959–69.Google Scholar
Ghaemi, N. S., Hsu, D. J., Soldani, F. and Goodwin, F. K. (2003). Antidepressants in bipolar disorder: the case for caution. Bipolar Disorders, 5, 421–33.Google Scholar
Ghaemi, S. N., Boiman, E. and Goodwin, F. K. (2000). Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. Journal of Clinical Psychiatry, 61, 804–8.Google Scholar
Grande, I., Berk, M., Birmaher, B. and Vieta, E. (2016). Bipolar disorder. Lancet. 387, 1561–72.Google Scholar
Hadjipavlou, G., Mok, H. and Yatham, L.N. (2004). Pharmacotherapy of Bipolar II disorder: a critical review of current evidence. Bipolar Disorders, 6, 14–25.Google Scholar
Hirschfeld, R. M. A. (2004). Bipolar depression: the real challenge. European Neuropsychopharmacology, 14, 83–8.Google Scholar
Hirschfeld, R. M., Weisler, R. H., Raines, S. R. and Macfadden, W. for the BOLDER Study Group (2006). Quetiapine in the treatment of anxiety in patients with Bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 67, 355–62.Google Scholar
Judd, L. L., Akiskal, H. S., Schetter, P. J. et al. (2002). The long-term natural history of the weekly symptomatic status of Bipolar I Disorder. Archives of General Psychiatry, 59, 530–7.Google Scholar
Khanna, S., Vieta, E., Lyons, B. et al. (2005). Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. British Journal of Psychiatry, 87, 229–34.Google Scholar
Kupka, R. W., Luckenbaugh, D. A., Post, R. M. et al. (2003). Rapid-and non-rapid-cycling bipolar disorder: a meta-analysis of clinical studies. Journal of Clinical Psychiatry, 64, 1483–94.Google Scholar
Kuyler, P. L. (1988). Rapid-cycling Bipolar II illness in three closely related individuals. American Journal of Psychiatry, 145, 114–15.Google Scholar
Loebel, A., Cucchiaro, J., Silva, R., et al. (2014a). Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. American Journal of Psychiatry. 171, 169–77.Google Scholar
Loebel, A., Cucchiaro, J., Silva, R., et al. (2014b). Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. American Journal of Psychiatry, 171, 160–8.Google Scholar
McElroy, S. L., Weisler, R. H., Chang, W. et al. (2010). A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). Journal of Clinical Psychiatry, 71, 163–74.Google Scholar
McIntyre, R. S., Mancini, D. A., Srinivasan, J. et al. (2004). The antidepressant effects of risperidone and olanzapine in bipolar disorder. Canadian Journal of Clinical Pharmacology, 11, e218–26.Google ScholarPubMed
Muzina, D. J. and Calabrese, J. R. (2005). Maintenance therapies in bipolar disorder: focus on randomised controlled trials. Australian and New Zealand Journal of Psychiatry, 39, 652–61.CrossRefGoogle Scholar
Quiroz, J. A., Yatham, L. N., Palumbo, J. M. et al. (2010). Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biological Psychiatry, 68,156–62.Google Scholar
Sachs, G. S., Ice, K. S., Chappell, P. B. et al. (2011). Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 72, 1413–22.Google Scholar
Solé, B., Martinez-Arán, A., Torrent, C. et al. (2011). Are bipolar II patients cognitively impaired? A systematic review. Psychological Medicine, 28, 1–13.Google Scholar
Suppes, T., Hirschfeld, R. M., Vieta, E. et al. (2006). Quetiapine monotherapy for depressive episodes in Bipolar II Disorder: combined results from two placebo-controlled studies. Bipolar Disorders, 8, S34–35.Google Scholar
Suppes, T., Kroger, H., Pikalov, A. and Loebel, A. (2016a). Lurasidone adjunctive with lithium or valproate for bipolar depression: a placebo-controlled trial utilizing prospective and retrospective enrolment cohorts. Journal of Psychiatry Research., 78, 86–93.Google Scholar
Suppes, T., Silva, R., Cucchiaro, J. et al. (2016b). Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. American Journal of Psychiatry, 173, 400–7.Google Scholar
Thase, M. E., Jonas, A., Khan, A. et al (2008). Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. Journal of Clinical Psychopharmacolgy, 28, 13–20.Google Scholar
Tohen, M., Vieta, E., Calabrese, J. et al. (2003). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of Bipolar I depression. Archives of General Psychiatry, 60, 1079–88.Google Scholar
Tohen, M., Vieta, E., Goodwin, G. M. et al. (2008). Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. Journal of Clinical Psychiatry, 69, 1776–89.Google Scholar
Torrent, C., Martinez-Aran, A., Daban, C. et al. (2006). Cognitive impairment in bipolar II disorder. British Journal of Psychiatry, 189, 254–9.Google Scholar
Vieta, E. (2003). Atypical antipsychotics in the treatment of mood disorders. Current Opinion in Psychiatry, 16, 23–7.Google Scholar
Vieta, E. (2009). Managing Bipolar Disorder in Clinical Practice. 2nd ed. London: Current Medicine Group.Google Scholar
Vieta, E. and Goikolea, J. M. (2005). Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disorders, 7, S1–S13.Google Scholar
Vieta, E., Calabrese, J. R., Goikolea, J. M. et al. (2007). Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disorders, 9, 413–25.Google Scholar
Vieta, E., Colom, F., Martínez-Arán, A. et al. (2000). Bipolar II disorder and comorbidity. Comprehensive Psychiatry, 41, 339–43.CrossRefGoogle ScholarPubMed
Vieta, E., Gasto, C., Colom, F. et al. (2001). Role of risperidone in Bipolar II: an open six-month study. Journal of Affective Disorders, 67, 213–19.Google Scholar
Vieta, E., Gastó, C., Otero, A. et al. (1997). Differential features between Bipolar I and Bipolar II disorder. Comprehensive Psychiatry, 38, 98–101.Google Scholar
Vieta, E., Grunze, H. (2011). Bipolar disorder: a focus on depression. New England Journal of Medicine, 364, 1581.Google Scholar
Vieta, E., Günther, O., Locklear, J. et al. (2011). Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. International Journal of Neuropsychopharmacology, 22, 1–21.Google Scholar
Vieta, E., Montgomery, S., Sulaiman, A. H., et al. (2012). A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. European Neuropsychopharmacology, 22, 825–35.Google Scholar
Vieta, E. and Suppes, T. (2008). Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disorders, 10, 163–78.Google Scholar
Yatham, L. N., Goldstein, J. M., Vieta, E. et al. (2005). Atypical antipsychotics in bipolar depression: potential mechanisms of action. Journal of Clinical Psychiatry, 66, 40–8.Google Scholar
Yildiz, A., Vieta, E., Leucht, S. et al. (2011). Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology, 36, 375–89.Google Scholar
Young, A. H., McElroy, S. L., Bauer, M. et al. (2010). A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). Journal of Clinical Psychiatry, 71, 150–62.Google Scholar
Young, A. H., McElroy, S. L., Olausson, B. et al. (2014) A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World Journal of Biological Psychiatry, 15, 96–112.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×